Triple negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases, which characterized by the absence of estrogen receptor, progesterone receptor, and HER2/neu expression (Marra et al., 2020). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.